J Korean Med Assoc.  2010 Nov;53(11):972-983.

Pharmacological treatment of psychiatric disorders of the elderly

• Won WY
• Lee CU

Abstract

Psychiatric disturbances in the elderly are complicated. Dementia and depression are serious causes of global impairment in the elderly. Aging is characterized by a progressive functional impairment of multiple organs, a reduction of homeostatic mechanisms, and a changed sensitivity or capacity of neurotransmitter receptors. Understanding the influence of age-dependent changes in the composition and function of the body on the pharmacokinetics and pharmacodynamics of drugs is important before prescribing drugs to elderly patients. However, there is little clinical pharmacological information available to guide pharmacotherapy for late-life psychiatric disorders. Treatment of dementia is based on the cognitive decline and behavioral symptoms that accompany dementia. Currently prescribed antidepressants have similar efficacies but the side effect profiles vary. Comprehension of the normal aging process and understanding the characteristics of each of the psychotropics are essential in geriatric psychopharmacology. Up to the present, most studies are confirmations or reproductions of previous results on efficacy or safety. Future directions for psychopharmacological research should include discovering newer drugs, treatment of resistance or nonresponders, and combination or adjunctive therapies. This review focused on the geriatric pharmacokinetic/pharmacodynamic changes and clinical information regarding currently prescribed psychotropic medications.

Keyword

Geriatric psychiatry; Psychopharmacology; Therapeutics; Dementia; Depression

MeSH Terms

Aged
Aging
Antidepressive Agents
Behavioral Symptoms
Comprehension
Dementia
Depression
Geriatric Psychiatry
Humans
Psychopharmacology
Receptors, Neurotransmitter
Antidepressive Agents
Receptors, Neurotransmitter

Reference

1. Cummings JL. Alzheimer's disease. N Engl J Med. 2004. 351:56–67.

2. Ostir GV, Goodwin JS. High anxiety is associated with an increased risk of death in an older tri-ethnic population. J Clin Epidemiol. 2006. 59:534–540.

3. Aparasu RR, Mort JR, Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc. 2003. 51:671–677.

4. Snowdon J, Day S, Baker W. Current use of psychotropic medication in nursing homes. Int Psychogeriatr. 2006. 18:241–250.

5. Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol. 2000. 20:137–140.

6. Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs. 2006. 20:143–151.

7. Friedman RA, Leon AC. Expanding the black box: depression, antidepressants, and the risk of suicide. N Engl J Med. 2007. 356:2343–2346.

8. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry. 2006. 163:813–821.

9. Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther. 2007. 81:899–902.

10. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995. 29:192–209.

11. Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch RA. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther. 2004. 76:618–627.

12. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006. 1:CD003491.

13. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006. 1:CD005593.

14. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008. 148:379–397.

15. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine MEM-MD-12 Study Group. Meman-tine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a rando-mized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008. 5:83–89.

16. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006. (2):CD003154.

17. Rosenberg C, Lauritzen L, Brix J, Jorgensen JB, Kofod P, Bayer LB. Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice. Psychopharmacol Bull. 2007. 40:63–73.

18. Wehmeier PM, Kluge M, Maras A, Riemann D, Berger M, Kohnen R, Dittmann RW, Gattaz WF. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. Pharmacopsychiatry. 2005. 38:13–16.

19. Oslin DW, Ten Have TR, Streim JE, Datto CJ, Weintraub D, DiFilippo S, Katz IR. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry. 2003. 64:875–882.

20. Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol. 2008. 28:32–38.